Associations - MSI-L/dMMR

MSI-L/dMMR MSI-L/dMMR	Small Intestinal Carcinoma Small Intestinal Carcinoma	MSI-L/dMMR MSI-L/dMMR	Small Intestinal Carcinoma Small Intestinal Carcinoma	dostarlimab Sensitive: A2 - Guideline	dostarlimab Sensitive: A2 - Guideline
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ipilimumab Sensitive: C3 – Early Trials	ipilimumab Sensitive: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Colorectal Cancer CRC	MSI-L/dMMR MSI-L/dMMR	Colorectal Cancer CRC	camrelizumab + SHR7390 Sensitive: C3 – Early Trials	camrelizumab + SHR7390 Sensitive: C3 – Early Trials